Ribomic Inc.
Domestic Phase III Trial of cartilage dysplasia treatment umsptanib pegol: Notice of Obtaining Informed Consent Exceeding Target Enrollment
Announced that informed consent obtained exceeded the target enrollment. Will steadily proceed with subject enrollment and focus on executing the WAKABA trial. No impact on full-year results for the fiscal year ending March 2027.
Key Figures
- Target number of enrolled subjects: 16 people (target stated in the text)
- Number of informed consents obtained: Exceeded target
- Impact on full-year results for fiscal year ending March 2027: Unknown → No impact
AI要約
Clinical Trial Progress and Drug Development Status
Ribomic Inc. is conducting a domestic Phase III clinical trial (WAKABA trial) in pediatric patients with achondroplasia (ACH) using umsptanib pegol (international nonproprietary name for RBM-007). The company announced that it has obtained informed consent from trial participants exceeding the target enrollment. Going forward, eligibility confirmations and required washout periods for concomitant medications will be completed and registrations will proceed, with focus on successful conduct of the trial. This matter will not affect the full-year results for the fiscal year ending March 2027.
Upcoming Schedule and Positioning of the Drug
Amid multiple ACH treatments under development, the early attainment of consents indicates expectations for this drug. The company will steadily advance subject enrollment and aims to continue and complete the trial. The drug is positioned as an orphan drug candidate that functions as an aptamer inhibiting FGF2 and may directly act on FGFR3-related pathophysiology.
Ribomic Inc.
Company overview · Stock price · Financial data · All IR
